Belumosudil With Ruxolitnib as Third Line Therapy for Chronic Graft Versus Host Disease (cGvHD)

NCT07643025 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

53

Enrollment

OTHER

Sponsor class

Conditions

cGVHD

Interventions

DRUG: Belumosudil
DRUG: Ruxolitinib

Sponsor

Dennis Kim

Collaborators

[object Object]